The American Cancer Society (ACS), the American Society for Colposcopy and Cervical Pathology (ASCCP), and the American Society for Clinical Pathology (ASCP) have released new guidelines for the prevention and early detection of cervical cancer. The guidelines generally advise a reduction in the number of tests women get over their lifetime to better ensure that they receive the benefits of testing while minimizing the harms, and include a preference for co-testing using the Pap test and HPV test for women age ages 30 to 65.
The finalized updated guidelines recommend:
The new guidelines are not intended for women with a history of cervical cancer, exposure to DES in utero, or women who are immunosuppressed (e.g. HIV positive). Costs and other financial issues were not considered in creating the guidelines.
"Pap tests have been done yearly in the past, but we now know that annual screening is not needed and in fact can lead to harm from treatment of cell changes that would never go on to cause cancer," said Debbie Saslow, PhD, director of breast and gynecologic cancer for the American Cancer Society. "Since 1980, organizations including the ACS have recommended less frequent screening. With the addition of the HPV test, we can test even less frequently, as the risk of pre-cancer and cancer when both tests are negative is so low. With these recommendations, our groups are helping to make sure women get the full lifesaving benefits of screening while minimizing its known harms."
Other new recommendations included in the guideline:
The updated guidelines were first released in draft form in late 2011. The working groups that created the draft guidelines then met with delegates from 25 organizations to further discuss and finalize the recommendations, which were then adapted into this final guideline.
"Our process resulted in guidelines that are focused on collectively presenting the best patient-centered cervical cancer screening strategies," said Mark Stoler, MD, past-president of the American Society for Clinical Pathology. "These final recommendations are based on a broad and emerging body of literature, and meld the very latest knowledge on the interplay between new molecular tests and traditional cytology."
"While these new guidelines reflect relatively small changes over previous screening recommendations, they are important," said Alan Waxman, M.D., incoming president of the American Society for Colposcopy and Cervical Pathology. "The addition of HPV testing to the Pap test in women 30 and over has been shown in recent studies to provide better protection for longer intervals from cancer and pre-cancerous changes than the use of the Pap test alone."
The guidelines are being published jointly in CA: A Cancer Journal for Clinicians (ACS), Journal of Lower Genital Tract Disease (ASCCP), and American Journal of Clinical Pathology (ASCP).
|Contact: David Sampson |
American Cancer Society